EGFR and non-small cell lung carcinoma: Among EGFR mutated NSCLC patients, BMs have an increased frequency, considering baseline incidence ranging from 23% to 32% [32,33,34,35] and a further risk of intracranial progression of about 15–20% during first-generation TKIs treatment [36,37].